This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Prostate cancer	Androgen receptor (AR); prostate-specific antigen (KLK3; PSA)	<p><i>In vitro</i> studies have identified indole carboxamide-based AR inhibitors that could help treat prostate cancer. In human prostate cancer cell lines, including one that is resistant to Xtandi enzalutamide, members from a series of indole carboxamide-based AR inhibitors decreased PSA production and cell proliferation at nanomolar to low micromolar IC₅₀ values. <i>In vitro</i>, the compounds were shown to target a region within the AR ligand-binding domain and not the androgen-binding domain. Next steps could include testing the lead compounds in animal models of prostate cancer.</p> <p>Medivation Inc. and Astellas Pharma Inc. market the oral AR antagonist Xtandi to treat prostate cancer. The drug also is in Phase III testing for breast cancer.</p> <p>AstraZeneca plc markets the oral nonsteroidal AR inhibitor Casodex bicalutamide to treat prostate cancer.</p> <p>Bayer AG markets the AR antagonist Androcur cyproterone acetate to treat prostate cancer.</p> <p>SciBX 7(32); doi:10.1038/scibx.2014.950 Published online Aug. 21, 2014</p>	Patent and licensing status unavailable	<p>Ban, F. <i>et al. J. Med. Chem.</i>; published online July 25, 2014; doi:10.1021/jm500684r</p> <p>Contact: Artem Cherkasov, The University of British Columbia, Vancouver, British Columbia, Canada e-mail: artc@interchange.ubc.ca</p>